Literature DB >> 16431350

Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.

Yaniv Sherer1, Yehuda Shoenfeld.   

Abstract

Intravenous immunoglobulin (IVIg) is used for replacement therapy in immunodeficiency states and for immunomodulation of various autoimmune diseases. Several case reports and series support a beneficial role of IVIg in systemic lupus erythematosus (SLE), both as salvage immunotherapy and in control of disease activity in general and amelioration of classical disease manifestations. Further, lupus nephritis can also be treated usually successfully with IVIg. A few questions remain unanswered as to the appropriate therapeutic dosage and the clinical manifestations that can be best treated with IVIg.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16431350     DOI: 10.1016/j.autrev.2005.09.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

2.  Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients.

Authors:  D Micheloud; M Calderón; M Caparrros; D P D'Cruz
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

Review 3.  Immunopathology of lupus nephritis.

Authors:  Hans-Joachim Anders; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

Review 4.  NK cells, autoantibodies, and immunologic infertility: a complex interplay.

Authors:  Caterina De Carolis; Carlo Perricone; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

Review 5.  SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.

Authors:  Marcella Prete; Elvira Favoino; Giacomo Catacchio; Vito Racanelli; Federico Perosa
Journal:  Int J Mol Sci       Date:  2020-05-10       Impact factor: 5.923

Review 6.  Hughes Syndrome: the antiphospholipid syndrome--a clinical overview.

Authors:  Graham Hughes
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.